Supernus Pharmaceuticals Stock Price To Earning

SUPN Stock

USD 36.57 0.42 1.14%

Supernus Pharmaceuticals fundamentals help investors to digest information that contributes to Supernus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Supernus Stock. The fundamental analysis module provides a way to measure Supernus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Supernus Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Supernus Pharmaceuticals Company Price To Earning Analysis

Supernus Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Supernus Pharmaceuticals Price To Earning

15.25 X

Most of Supernus Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Supernus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Supernus Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Supernus Pharmaceuticals is extremely important. It helps to project a fair market value of Supernus Stock properly, considering its historical fundamentals such as Price To Earning. Since Supernus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Supernus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Supernus Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.89	0.8	0.85	-0.07	0.92	0.85	0.97	0.99	0.8	0.65	0.71	0.87	0.38	0.81	0.22	0.78	0.84	0.91	0.85	0.49	0.82	0.95	0.6	0.37
Total Stockholder Equity	0.89		0.57	0.97	-0.26	0.98	0.77	0.81	0.87	0.89	0.61	0.49	0.96	0.29	0.94	0.13	0.95	0.93	0.9	0.91	0.3	0.9	0.94	0.51	0.75
Net Debt	0.8	0.57		0.58	0.17	0.62	0.83	0.88	0.82	0.53	0.32	0.68	0.63	0.53	0.48	0.24	0.43	0.54	0.57	0.62	0.52	0.54	0.78	0.39	0.1
Retained Earnings	0.85	0.97	0.58		-0.24	0.94	0.75	0.78	0.83	0.92	0.43	0.45	0.94	0.31	0.96	0.04	0.95	0.89	0.81	0.89	0.21	0.86	0.93	0.44	0.77
Accounts Payable	-0.07	-0.26	0.17	-0.24		-0.27	0.03	0.01	-0.08	-0.15	-0.09	0.24	-0.25	0.22	-0.2	-0.08	-0.28	-0.25	-0.27	-0.12	0.0	-0.27	-0.11	-0.2	-0.35
Net Receivables	0.92	0.98	0.62	0.94	-0.27		0.79	0.86	0.92	0.88	0.66	0.49	0.93	0.35	0.91	0.15	0.93	0.94	0.92	0.89	0.34	0.91	0.94	0.53	0.66
Short Term Investments	0.85	0.77	0.83	0.75	0.03	0.79		0.81	0.89	0.67	0.56	0.43	0.76	0.68	0.65	0.2	0.67	0.71	0.74	0.68	0.37	0.69	0.84	0.26	0.37
Total Liab	0.97	0.81	0.88	0.78	0.01	0.86	0.81		0.97	0.74	0.57	0.77	0.82	0.37	0.73	0.24	0.69	0.77	0.82	0.82	0.55	0.76	0.94	0.64	0.3
Total Current Assets	0.99	0.87	0.82	0.83	-0.08	0.92	0.89	0.97		0.75	0.66	0.66	0.87	0.43	0.76	0.29	0.75	0.84	0.89	0.81	0.53	0.83	0.94	0.6	0.36
Intangible Assets	0.8	0.89	0.53	0.92	-0.15	0.88	0.67	0.74	0.75		0.42	0.4	0.81	0.36	0.97	-0.31	0.96	0.75	0.73	0.9	-0.07	0.7	0.86	0.27	0.69
Common Stock	0.65	0.61	0.32	0.43	-0.09	0.66	0.56	0.57	0.66	0.42		0.39	0.52	0.25	0.46	0.34	0.48	0.6	0.83	0.51	0.44	0.6	0.54	0.41	0.21
Current Deferred Revenue	0.71	0.49	0.68	0.45	0.24	0.49	0.43	0.77	0.66	0.4	0.39		0.52	0.04	0.45	0.36	0.3	0.46	0.54	0.53	0.66	0.46	0.66	0.66	0.04
Long Term Debt	0.87	0.96	0.63	0.94	-0.25	0.93	0.76	0.82	0.87	0.81	0.52	0.52		0.15	0.88	0.23	0.86	0.9	0.86	0.92	0.42	0.88	0.95	0.64	0.7
Short Term Debt	0.38	0.29	0.53	0.31	0.22	0.35	0.68	0.37	0.43	0.36	0.25	0.04	0.15		0.25	-0.11	0.31	0.23	0.23	0.14	-0.09	0.22	0.33	-0.41	0.09
Property Plant Equipment	0.81	0.94	0.48	0.96	-0.2	0.91	0.65	0.73	0.76	0.97	0.46	0.45	0.88	0.25		-0.17	0.97	0.82	0.79	0.91	0.04	0.76	0.88	0.38	0.77
Net Tangible Assets	0.22	0.13	0.24	0.04	-0.08	0.15	0.2	0.24	0.29	-0.31	0.34	0.36	0.23	-0.11	-0.17		-0.16	0.3	0.29	-0.05	0.91	0.36	0.17	0.57	-0.11
Good Will	0.78	0.95	0.43	0.95	-0.28	0.93	0.67	0.69	0.75	0.96	0.48	0.3	0.86	0.31	0.97	-0.16		0.86	0.8	0.89	0.0	0.81	0.85	0.32	0.8
Long Term Debt Total	0.84	0.93	0.54	0.89	-0.25	0.94	0.71	0.77	0.84	0.75	0.6	0.46	0.9	0.23	0.82	0.3	0.86		0.87	0.83	0.44	1.0	0.87	0.58	0.65
Capital Surpluse	0.91	0.9	0.57	0.81	-0.27	0.92	0.74	0.82	0.89	0.73	0.83	0.54	0.86	0.23	0.79	0.29	0.8	0.87		0.83	0.47	0.85	0.86	0.6	0.48
Deferred Long Term Liab	0.85	0.91	0.62	0.89	-0.12	0.89	0.68	0.82	0.81	0.9	0.51	0.53	0.92	0.14	0.91	-0.05	0.89	0.83	0.83		0.23	0.79	0.91	0.54	0.64
Long Term Investments	0.49	0.3	0.52	0.21	0.0	0.34	0.37	0.55	0.53	-0.07	0.44	0.66	0.42	-0.09	0.04	0.91	0.0	0.44	0.47	0.23		0.49	0.43	0.77	-0.1
Short Long Term Debt	0.82	0.9	0.54	0.86	-0.27	0.91	0.69	0.76	0.83	0.7	0.6	0.46	0.88	0.22	0.76	0.36	0.81	1.0	0.85	0.79	0.49		0.84	0.6	0.61
Net Invested Capital	0.95	0.94	0.78	0.93	-0.11	0.94	0.84	0.94	0.94	0.86	0.54	0.66	0.95	0.33	0.88	0.17	0.85	0.87	0.86	0.91	0.43	0.84		0.59	0.59
Net Working Capital	0.6	0.51	0.39	0.44	-0.2	0.53	0.26	0.64	0.6	0.27	0.41	0.66	0.64	-0.41	0.38	0.57	0.32	0.58	0.6	0.54	0.77	0.6	0.59		0.15
Capital Stock	0.37	0.75	0.1	0.77	-0.35	0.66	0.37	0.3	0.36	0.69	0.21	0.04	0.7	0.09	0.77	-0.11	0.8	0.65	0.48	0.64	-0.1	0.61	0.59	0.15

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Supernus Pharmaceuticals

Supernus Retained Earnings

Retained Earnings

506.69 Million

At this time, Supernus Pharmaceuticals' Retained Earnings are very stable compared to the past year.

Based on the latest financial disclosure, Supernus Pharmaceuticals has a Price To Earning of 15.25 times. This is 40.98% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 46.9% higher than that of the company.

Supernus Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Supernus Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Supernus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Supernus Pharmaceuticals by comparing valuation metrics of similar companies.

Supernus Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Supernus Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Supernus Pharmaceuticals from analyzing Supernus Pharmaceuticals' financial statements. These drivers represent accounts that assess Supernus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Supernus Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.2B	1.3B	1.5B	1.9B	1.6B	1.7B
Enterprise Value	1.4B	1.4B	1.8B	2.3B	1.5B	1.6B

Supernus Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Supernus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Supernus Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Supernus Fundamentals

	Return On Equity	0.0622
	Return On Asset	0.0289
	Profit Margin	0.09 %
	Operating Margin	0.16 %
	Current Valuation	1.65 B
	Shares Outstanding	55.22 M
	Shares Owned By Insiders	5.01 %
	Shares Owned By Institutions	94.99 %
	Number Of Shares Shorted	6.52 M
	Price To Earning	15.25 X
	Price To Book	2.00 X
	Price To Sales	3.13 X
	Revenue	607.52 M
	Gross Profit	580.02 M
	EBITDA	90.04 M
	Net Income	1.32 M
	Cash And Equivalents	360.79 M
	Cash Per Share	6.74 X
	Total Debt	41.53 M
	Debt To Equity	0.53 %
	Current Ratio	0.85 X
	Book Value Per Share	18.24 X
	Cash Flow From Operations	111.08 M
	Short Ratio	16.46 X
	Earnings Per Share	1.07 X
	Price To Earnings To Growth	1.47 X
	Target Price	39.25
	Number Of Employees	652
	Beta	0.87
	Market Capitalization	2.04 B
	Total Asset	1.28 B
	Retained Earnings	482.56 M
	Working Capital	202.92 M
	Current Asset	105.95 M
	Current Liabilities	56.93 M
	Net Asset	1.28 B

About Supernus Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Supernus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Supernus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Supernus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Supernus Stock

0.79

FNMFO

Federal National Mortgage

Pair Corr

Moving against Supernus Stock

0.87	HLN	Haleon plc	Pair Corr
0.75	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.71	BCH	Banco De Chile	Pair Corr
0.67	ANRO	Alto Neuroscience,	Pair Corr
0.61	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Supernus Pharmaceuticals Piotroski F Score and Supernus Pharmaceuticals Altman Z Score analysis.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

1.07

Revenue Per Share

11.877

Quarterly Revenue Growth

0.142

Return On Assets

0.0289

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Pharmaceuticals Stock Price To Earning

Supernus Pharmaceuticals Company Price To Earning Analysis

P/E

Market Value Per Share

Earnings Per Share

Current Supernus Pharmaceuticals Price To Earning

Supernus Price To Earning Driver Correlations

Supernus Retained Earnings

Retained Earnings

506.69 Million

Supernus Price To Earning Peer Comparison

Supernus Pharmaceuticals Current Valuation Drivers

Supernus Pharmaceuticals ESG Sustainability

Supernus Fundamentals

About Supernus Pharmaceuticals Fundamental Analysis

Pair Trading with Supernus Pharmaceuticals

Moving together with Supernus Stock

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY